Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies.
Episode Highlights: 
• KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma 
• AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer 
• ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now 
• NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies
YouTube: https://youtu.be/Rt8HQpdyVY0
Follow us on social media: 
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers 
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers 
•⁠  Website: https://oncbrothers.com/
Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies.
Episode Highlights: 
• KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma 
• AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer 
• ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now 
• NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies
YouTube: https://youtu.be/Rt8HQpdyVY0
Follow us on social media: 
•⁠ &nbsp;⁠X/Twitter: https://twitter.com/oncbrothers 
•⁠ &nbsp;⁠Instagram: https://www.instagram.com/oncbrothers 
•⁠ &nbsp;Website: https://oncbrothers.com/
Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.

Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. 

Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. 

Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.

If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com

Medicine

Health & Fitness

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology &amp; oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.

Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. 

Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. 

Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.

If you want to navigate the complexities of your hematology &amp; oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com

Share ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

Sign up to save your podcasts

ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

More shows like Oncology Brothers: Practice-Changing Cancer Discussions

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Mayo Clinic Talks

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

The ONS Podcast

OncoPharm

ASCO Guidelines

OncLive® On Air

Becker’s Healthcare Podcast

Oncology Today with Dr Neil Love

Two Onc Docs